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Background: Small molecules as shown by VX809 can rescue the mislocalization of F508del-CFTR. The aim of this study was to identify
correctors with a clinical history and their targets of action.
Methods: CFTR correctors were screened using two F508del-CFTR expressing cell based HTS assays. Electrophysiological studies using
CFBE41o− and HBE cells and in-vivo mouse assays conﬁrmed CFTR rescue. The target of action was attained using pharmacological inhibitors
and siRNA to speciﬁc genes.
Results: Ibuprofen was identiﬁed as a CFTR corrector. Ibuprofen treatment of polarized CFBE41o− monolayers increased the short-circuit current
(Isc) response to stimulation. In vivo CF mice treatment with ibuprofen restored the CFTR trafﬁcking. SiRNA knock down of cyclooxygenase
expression caused partial F508del-CFTR correction.
Conclusion: These studies show that ibuprofen is a CFTR corrector and that it causes correction by COX-1 inhibition. Hence ibuprofen may be
suitable to be part of a future CF combination therapy.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; NSAID; Protein folding; Protein trafﬁcking1. Introduction
Cystic fibrosis (CF) is a lethal autosomal recessive disease
triggered by mutations in the gene encoding the CF transmem-
brane conductance regulator protein [1]. The most common
disease-associated mutation is a deletion of the phenylalanine
residue at position 508 (F508del-CFTR) with approximately
70% of all CF patients being homozygous for this mutation.
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proteasome system [2,3]. However, if cells are incubated at
reduced temperature a small portion of newly synthesized
F508del-CFTR does traffick to the cell surface where it is a
partially functional anion channel [3,4].
The ability to rectify the location of F508del-CFTR has
heightened the interest in drug development for this purpose.
Several groups undertook high throughput-screening (HTS)
projects to identify small molecules that correct F508del-CFTR
trafficking [5–7] with Vx-809 (ivacaftor) the only drug that has
completed monotherapy testing in the clinic [8].
Our goal here is to test known drugs that were developed
for other indications for their ability to correct F508del-CFTR
trafficking. Such compounds have known safety and bioavail-
ability hence potentially reducing the time needed for pre-clinicalll rights reserved.
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compound we identified was ibuprofen.
Ibuprofen was first investigated as a CF treatment in 1990 and
is currently used in CF patients to reduce extreme inflammation
[9]. Ibuprofen was found to significantly slow the decline in
FEV1 over a four-year period and this has been confirmed in
subsequent studies [10–12]. The effect of ibuprofen has been
attributed to its anti-inflammatory effect based, in part, on early
rat model studies of Pseudomonas infection [9].
We identified ibuprofen in a cell-based HTS assay specifically
designed to detect F508del-CFTR trafficking correctors. Here
we evaluated ibuprofen corrector potency for F508del-CFTR
processing in several in vitro model systems including polarized
epithelial cells, primary human airway epithelial cell monolayers,
and freshly isolated intestines from CF mice. We found partial
CFTR correction in all these systems. Also, in an in-vivo
F508del-CFTR mouse assay ibuprofen gave correction. Here we
further show that the target of action for ibuprofen induced CFTR
correction maybe via inhibition of the COX protein family
particularly COX-1. Hence the CF patient benefit of ibuprofen
treatment is not only due to reducing inflammation but also due to
CFTR correction.
2. Methods
2.1. Materials used
Four specific cyclooxygenase (COX) inhibitors were
used; the COX1 inhibitors Sc560 (5-(4-chlorophenyl)-1-
(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole) [13]
and TFAP (N-(5-amino-2-pyridinyl)-4-trifluoromethylbenzamide)
[14] the COX2 inhibitors DuP 697 (5-bromo-2-(4-fluorophenyl)-
3-(4-(methylsulfonyl) phenyl)-thiophene) [15] and NPIMA
(N-(3-pyridyl)-indomethacin amide) [16] (all from Cayman
Chem.).
2.2. Cell culture
The CFBE cell line used is the CFBE41o− derived from
CF patients bronchial epithelial cells and stably infected with
TranzVector lentivectors containing either wt or F508del-CFTR.
Theywere kindly provided by J.P. Clancy (University of Alabama,
Birmingham, USA) [17]. Wild-type V2R and V2R-V206D were
provided by Dr. Peter Deen (NCMLS, The Netherlands). HEK
cells stably expressing HA-tagged hERG G601S or wild-type
hERG were given by Eckhard Ficker (Case Western Reserve
University U.S.A.) Flag-tagged hamster SUR1 both the wild-type
and A116P mutant form and rat Kir6.2 plasmids were given by
Show-Ling Shyng (Oregon Health and Science University) and
were reported previously [18].
2.3. HTS protocol
Screening was performed as described previously (and
supplementary methods) using BHK cells that express F508del-
CFTR with 3 tandem hemagglutinin-epitope tags (3HA) in the
fourth extra-cellular loop [19].2.4. YFP fluorescence assay
Compounds were counter screened as previously described
(and supplementary methods) using Human Embryonic Kidney
cells (HEK293GripTite™, Invitrogen) stably expressing F508del-
CFTR that was transfected with a halide sensitive variant of
eYFP [6].
2.5. Transfection for non-CF protein diseases
HeLa cells (5.0 × 106 cells/flask) were transfected with 16 μg
of plasmid and 60 μl of fugene HD overnight. The next day cells
were transferred to 6 well dishes (1.0–1.2 × 106 cells/well) and
24 h later treated with the compound of interest for 24 h [18].
2.6. Immunoblots
Immunoblots were used to measure CFTR maturation using
a mouse monoclonal anti-CFTR primary antibody (24-1; R&D
Systems USA. Cat. MAB25031) and a secondary antibody, HRP-
conjugated anti-mouse antibody (Amersham).
2.7. Iodide efflux assay
Iodide efflux was used to measure CFTR functionality in
BHK cells as described in supplementary methods and previously
[5].
2.8. Voltage-clamp of CFBE41o− cell monolayers
Short-circuit current (Isc) was measured across CFBE41o
− cell
monolayers in Ussing chambers as stated previously [6] and in
the supplementary materials.
2.9. CF mice
Homozygous F508del-CFTR mutant mice (Cftrtm1Eur; [6])
and non-CF littermate controls on a FVB background were used.
Canadian Institutes of Health Research (CIHR) guidelines were
followed and approved by the McGill University Animal Care
Committee. Mice were genotyped by PCR [6]. Compounds were
tested in-vivo and ex-vivo: as described previously [6] (and in
supplementary methods).
2.10. High-throughput FACS assay for siRNA treatment
HEK293 Flp-In T-Rex cells were utilized as discussed in
the supplementary materials and previously [5] to measure the
increase in surface CFTR upon siRNA treatment.
2.11. RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted and real-time PCR assays were
performed as described previously and in supplementary materials
[6].
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Statistical analysis was performed as described previously
and in supplementary materials [6].
3. Results
3.1. Ibuprofen partially corrects the F508del-CFTR trafficking
defect
Ibuprofen was identified as a CFTR corrector from a screen
of 3200 known drugs from commercial compound libraries
(Supplemental Table 1 and supplementary information) (Fig. 1A).
Ibuprofen gave a 25.7 ± 1.6% increase in cell surface F508del-
CFTR signal as compared to wild type signal (Fig. 1B). By
comparison, the known corrector VRT-325 gave a 39.5 ± 1.3%
increase. However, ibuprofen appeared to have no effect on
wild-type CFTR trafficking (Fig. 1B). Ibuprofen was counter
screened using an enhanced YFP fluorescence-quenching halide
influx assay (Fig. 1C). Ibuprofen gave a functional response that
was 38% of the response elicited by VRT-325. To measure
ibuprofen potency as a F508del-CFTR trafficking corrector, a
series of concentrations and exposure times were tested using the
HTS protocol (Fig. 1D, E). Ibuprofen increased surface expression
significantly after 24 h treatment over a broad concentration range
(100 pM, to 500 μM) with a peak value of 28.5 ± 2.1% of the
wild-type surface signal at 10 μM. The response to ibuprofen
(10 μM) first appeared after 4 h treatment peaking at 24 h, and
lasting until 48 h.
3.2. Corrector validation of ibuprofen
CFTR protein maturation upon ibuprofen treatment was
determined by immunoblotting. Maturation was indicated by
the appearance of the mature glycosylated (band C) CFTR form
in BHK cells after ibuprofen (10 μM) treatment (24 h) (Fig. 2A).
Immature CFTR levels also increased upon ibuprofen treatment.
The correction level was measured semi-quantitatively and
displayed as a percentage of the total amount of CFTR detected
in each lane. (Fig. 2B). Ibuprofen treatment increased the level of
mature band C with 12% of the CFTR detected in the lane being
band C. In comparison VRT-325 (10 μM) increased the amount
of band C to 33% of the total CFTR. Neither VRT-325 nor
ibuprofen increased the CFTR mRNA level as measured by
quantitative rtPCR (data not shown). Hence the increases in
levels of band B upon ibuprofen treatment may have been due to
increased protein stability due to better F508del-CFTR folding or
alternatively to increased protein synthesis caused by increased
polysomal loading on the CFTR mRNA or possibly both.
Ibuprofen was tested on a human cell line derived from a CF
patient (CFBE41o−) expressing F508del-CFTR (Fig. 2C).
To address our own data (Fig. 1D) and the previous research
demonstrating positive responses obtained from high ibuprofen
doses we chose to used a high ibuprofen dose comparable to
clinical trials (320 μM) [11,12]. The F508del cell line
expresses significantly more band B than wild type even in the
vehicle only sample. Ibuprofen generated an increase in band C(at 10 μM and 320 μM) to 14 ± 1.2% of the amount of CFTR in
the lane. In comparison VRT-325 (10μM) had 26% of its CFTR
expressed in the band C form.
To determine if the corrected F508del-CFTRwas functional it
was measured using an automated iodide efflux assay. Ibuprofen
treatment (10 μM) for 24 h caused recovery of halide efflux
responses to 10 μM forskolin + 50 μM genistein (Fig. 3A).
Correction was less robust than VRT-325 treatment or in cells
expressing wild-type CFTR, consistent with the HTS assays and
immunoblots. Ibuprofen correction potency and dynamics were
tested (Fig. 3B, C). Doses between 10 nM and 500 μM of
ibuprofen caused a significant F508del-CFTR iodide efflux
restoration peaking at 10 μM, consistent with the HTS assay for
protein trafficking. Ibuprofen gave a significant response after
treatment with a single dose of 10 μM for 18 to 48 h.
3.3. Ibuprofen functionally rescues CFTR, in polarized human
CF derived cells
By monitoring CFTR-dependent short-circuit current across
polarized CFBE41o− cell monolayers expressing recombinant
F508del-CFTR in Ussing chambers we tested ibuprofen at two
concentrations (10 μM and 320 μM) (24 h) (Fig. 3D and
Supplementary Fig. 1). After DMSO normalization, ibuprofen
treatment enabled (forskolin + genistein) stimulated currents,
corresponding to 2.1 and 4.4% (10 and 320 μM ibuprofen
respectively) of the low-temperature correction which is equiva-
lent to 1.1 and 2.2% of the response obtained from wild-type
CFTR. This response was CFTRinh-172 sensitive, indicating
CFTR dependence (data not shown).
Given the chronic nature of Cystic Fibrosis and the previous
clinical data suggesting that ibuprofen had a stronger effect over
time, we decided to examine ibuprofen corrector ability over
7 days (Fig. 3E) using polarized CFBE41o− cell monolayers in
Ussing chambers. We tested ibuprofen at two concentrations
(10 μM and 320 μM) for 7 days. After DMSO normaliza-
tion, ibuprofen treatment at 10 μM no longer enabled small
(forskolin + genistein) stimulated currents. However the high
dose (320 μM) ibuprofen treatment stimulated currents, corre-
sponding to 5.6% of the low temperature response equivalent to
2.6% of CFBE41o− cells expressing wild-type CFTR.
3.4. Ibuprofen rescues functional CFTR in fully differentiated
primary polarized human bronchial epithelial cells (HBE)
Next ibuprofen ability to correct mislocalized CFTR was
tested (Fig. 3F and Supplementary Fig. 2) by monitoring
CFTR-dependent short-circuit current across polarized HBE
cell monolayers in Ussing chambers and for a yet longer time
period. Cells were treated for 16 days with 320 μMof ibuprofen.
Of the three patient samples tested one did not respond (patient
3), one (patient 1) gave a very modest positive response (0.14%
of non-CF response), however the third patient sample (patient 2)
gave a small but significant response equivalent to 1.1% of
non-CF cells. This is approximately 10% of the response
obtained by the best-reported compound VX-809 (ivacaftor)
(Fig. 3F).
Fig. 1. Ibuprofen corrects F508del-CFTR mislocalization. (A) Chemical structure of ibuprofen. (B) Changes in F508del-CFTR surface expression in BHK cells
after 24 h treatment with ibuprofen (10 μM) or VRT-325 (10 μM), as compared to wild-type protein surface expression. Data presented as mean ± S.E.M.
(N = 6) and are compared with the control. (C) Fluorescence quenching by iodide influx in HEK293 cells co-expressing F508del-CFTR and a halide-sensitive
eYFP. Cells were pretreated for 24 h with 0.1% DMSO (negative control) (vehicle, n = 3), 10 μM ibuprofen (ibuprofen, n = 3), or 10 μM VRT-325 (positive
control) (VRT-325, n = 3). F508del-CFTR functional correction was assayed by the quenching of YFP fluorescence with iodide in the presence of 25 μM
forskolin, 45 μM 3-isobutyl-1-methylxanthine, and 50 μM genistein. (D). Concentration gradient of ibuprofen in the BHK surface expression assay after 24 h
pretreatment, data are presented as mean ± SEM (n = 6). (E) Time course of correction after 1–96 h ibuprofen treatments at 10 μM in the BHK cell screen
assay. Data presented as means ± SEM (n = 6). Significance compared with vehicle alone was determined using an unpaired t test, *p b 0.05, **p b 0.01,
***p b 0.001.
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Fig. 2. Ibuprofen correction of F508del-CFTR. (A) Immunoblot showing F508del-CFTR in BHK cell lysates treated with 10 μM ibuprofen for 24 h. F508del-CFTR
cells were treated with vehicle (0.1% DMSO;) or with 10 μM VRT-325 as controls. Wild-type CFTR expressing BHK cells (wt) are shown for comparison. B and C
are the mature, complex-glycosylated form of CFTR and band B is the core-glycosylated immature glycoform. Tubulin was used as a loading control.
(B) Quantification of immunoblots by densitometry of four independent experiments monitoring the relative amounts of bands C and B detected in each lane stated as
a percentage of the total CFTR detected in that lane. (C) Similar experiment to part A except that it is undertaken in polarized CFBE41o− cells expressing
F508del-CFTR. (D) The 4 similar immunoblots to part C are quantified as per part B. Note in parts B and D significance compared with vehicle alone (control) was
determined using an unpaired t test, *p b 0.05, **p b 0.01, ***p b 0.001. Data are presented as the mean ± S.E.M.
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murine CF models
To test ibuprofen correction in a complex biological system,
intestinal sections removed from F508del-CFTR homozygous
mice and their littermate controls (non-CF) were incubated with
10 μM ibuprofen (4 h) and monitored in Ussing chambers
(Fig. 4A and Supplementary Fig. 3). After normalization 10 μM
ibuprofen significantly increased the response to 10 μM
forskolin + 50 μM genistein by 8%. This represents ~2.8%
of the wild-type mouse response (N = 3), (Fig. 4B).
To test ibuprofen in-vivo, we measured ß-adrenergic-stimulated
salivary secretion in F508del-CFTR mice. Ibuprofen was admin-
istered at 0.15 mg/kg/day (48 h) by a subcutaneous micro-pump
equivalent to 10 μM, (Fig. 4B). Ibuprofen treatment led to a
2.5-fold increase in saliva production which corresponds to 5%
rescue of the salivary secretion in non-CF controls.
In conclusion the data indicates that ibuprofen partially
rescues F508del-CFTR processing and increases functional
CFTR at the cell surface. Intriguingly when tested in combinationwith other previously reported correctors, ibuprofen demonstrat-
ed a significant additive effect on CFTR rescue on a subset of
these in particular VX-809 (Ivacaftor) (Supplementary Fig. 4).
3.6. Ibuprofen correction is specific to CFTR
Cystic fibrosis is one of a number of protein misfolding
diseases [18]. To determine if ibuprofen's corrector ability is
unique to CFTR we tested three other trafficking disease models
(Supplementary Fig. 5). The Long QT syndrome type 2 (LQTS2)
mutation G601S in the human ether-a-go-go-related gene
(hERG) was treated for 24 h and immunoblotted. Correction
for hERG as can be seen by the treatment at 29 °C or with
astemizole, it is an upward migration of the core hERG band.
This upward migration can also be seen in the wild-type hERG
lane which is provided for comparison. Ibuprofen gave no
correction at any of the concentrations tested (Supplementary
Fig. 5A). The nephrogenic diabetes insipidus mutation V206D in
the arginine vasopressin receptor 2 (V2R) expressed in HeLa
cells and treated with ibuprofen (24 h). Correction was marked
Fig. 3. Functional ibuprofen correction of F508del-CFTR. (A) Iodide efflux assay of F508del-CFTR at the plasma membrane of BHK cells after treatment with
10 μM ibuprofen for 24 h (n = 16). Control cells received vehicle alone (0.1% DMSO, n = 16). Positive controls 10 μM VRT-325 for 24 h (n = 16), and wild-type
CFTR (n = 14). Stimulationwas by forskolin (Fsk) (10 μM) and genistein (Gst) (50 μM). Note the error in this experiment was small hence the error bars are often masked
by the symbol (B). Functional rescue on ibuprofen concentration gradient. BHK cells expressing F508del-CFTRwere treated (24 h) before measuring iodide efflux (n = 8
for each concentration). Results are also shown for control cells receiving vehicle alone (0.1%DMSO) and cells pretreated with 10 μMVRT-325 (24 h) (C) Time course of
correction. BHK cells expressing F508del-CFTR were treated with 10 μM ibuprofen for 1 to 96 h (n = 8), response of VRT-325 (10 μM; n = 8). (D) Polarized human
epithelial airway cells (CFBE41o−) expressing F508del-CFTR were incubated for 24 h with Ibuprofen (10 μM and 320 μM) and assayed for forskolin (10 μM) and
genistein (50 μM) stimulation in Ussing chambers. Mean ± S.E.M. (n = 8). (E) CFBE41o− cells expressing F508del-CFTR were incubated for 7 days with Ibuprofen
(10μMand 320μM) and assayed as per part D. (F) Polarized human primary bronchial epithelial cells (HBE) derived from lung transplants fromCF patients were incubated
for 16 days with ibuprofen (320 μM) and assayed with forskolin (10 μM) and genistein (50 μM) in Ussing chambers. Mean ± S.E.M.
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the 75 kilodalton marker as may be seen upon low temperature
(29 °C) treatment and with wild-type V2R. Ibuprofen treatment
at all concentrations tested proved negative (Supplementary
Fig. 5B). Persistent hyperinsulinemic hypoglycemia of infancy
mutation A116P in the sulfonylurea receptor 1 (SUR1) expressedin HeLa cells was treated (24 h) with ibuprofen. A positive
response (Glibenclamide treatment) is the appearance of a higher
molecular weight complex glycosylated form of SUR1. Wild-
type SUR1 which similar to Glibenclamide gave a higher
molecular weight band was added for comparison. Ibuprofen
gave a negative response (Supplementary Fig. 5C). Taken
Fig. 4. Ibuprofen corrects in ex-vivo and in-vivomodels (A) Ibuprofen (10 μM) functional correction quantified ex vivo. Change in Isc (Isc) after forskolin (10 μM) and
genistein (50 μM) stimulation. Stimulation of Isc across sections of ileum from several mice was undertaken (F508del-CFTR) before (0 h) and after (4 h) pretreatment
with vehicle (n = 18 ileum fromN = 6 mice), ibuprofen (n = 20 ileum fromN = 6mice), or wild-type mice (wt; n = 11 ileum fromN = 4mice) for 4 h. Mean ± S.E.M.,
comparison with respective control at time 0 h was determined using an unpaired t test. Note break in y-axis. (B) Ibuprofen functional correction quantified in vivo
monitored by salivary secretion. Total saliva secreted by wild-type mice (wt; n = 6), CF mice treated with vehicle alone (n = 6) or with ibuprofen (50 μg/h for 2 days)
(ibuprofen; n = 6). Data are presented as the mean ± S.E.M with significance determined using an unpaired t test, *p b 0.05, **p b 0.01, ***p b 0.001, when comparing
CF mice treated with vehicle alone and CF mice treated with ibuprofen.
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not universal in nature.
3.7. Ibuprofen correction works via inhibition of COX
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID)
that functions by inhibiting two isoforms of cyclooxygenase
(COX), COX 1 and COX 2. To determine if COX inhibition
alone triggers F508del-CFTR rescue COX inhibitors were tested
in the HTS assay (Fig. 5A). Among those, the COX 1 inhibitors
(SC-560 and TFAP) both gave positive responses in particular
SC-560 gave a cell surface signal of CFTR 1.5-fold larger than
ibuprofen. However, two COX 2 inhibitors (DUP-697 and
N-(3-pyridyl)-Indomethacin amide [NPIMA]) failed to increase
F508del-CFTR trafficking. To determine if this CFTR rescuewas
functional, BHK cells were each treated for 24 h separately withFig. 5 Speciﬁc COX 1 inhibitors trigger correction of F508del-CFTR. (A) BHK cells
TFAP (cyclooxygenase 1 [COX 1] inhibitors), DUP-697 (cyclooxygenase-2 [COX
monitored using the HTS assay (n = 6). Mean ± S.E.M. (B). Iodide efﬂux was used
upon testing with COX inhibitors (as in A) (n = 8). Control is treated with vehicle a
were tested at 10 μM for 24 h prior to efﬂux assay.(C.) Ussing chamber assay of
current response to 10 μM forskolin and 50μM genistein after 24 h exposure of cell
and SC-560 + DUP-697. Data are presented as mean ± S.E.M. An unpaired t test was
CFTR expression in HEK293 cells expressing F508del-CFTR in a Flp-In T-Rex system
combination). Also shown for comparison are scrambled siRNA plus vehicle (DMSO
knockdown was performed 48 h before surface CFTR FACS assay. Ibuprofen treatmen
were monitored in HEK293 cells expressing F508del-CFTR and treated with various co
10 μM and 100 μM) in combination with siRNA knockdown of expression of COX
knocked down 24 h prior to the 24-hour ibuprofen treatment. The level of siRNA knock
part A (see Supplementary Fig. 6). Two control sets of cells were tested for each conc
(Control black) and secondly a set of cells with a mock transfection and ibuprofen treatm
vehicle alone was determined using an unpaired t test, *p b 0.05, **p b 0.01, ***p beach compound of interest (10 μM) and then monitored using the
halide efflux assay (Fig. 5B). Consistent with the HTS assay,
halide effluxes were positive with the COX 1 inhibitors SC-560
and TFAP but the COX 2 inhibitors (DUP-697 and NPIMA)
were not statistically significant. COX 1 and COX 2 were also
studied using polarized CFBE41o− epithelial cells mounted in
Ussing chambers (Fig. 5C). COX 1 inhibition gave small but
significant correction (3.7% of low temperature response, 1.85%
of wild-type response) similar to that obtained with ibuprofen,
whereas COX 2 did not.
To confirm COX inhibition as a mechanism of F508del-CFTR
trafficking correction by NSAIDs, siRNAs that target COX 1 and
COX 2 were used to rescue F508del-CFTR function in HEK293
cells (Fig. 5D). HEK293 cells expressing F508del-CFTR were
used as siRNA for human cells is more straightforward. The cells
were siRNA transduced with COX-1, COX-2 and a combinationexpressing F508del-CFTR-3HA were treated (24 h) with ibuprofen, SC-560 and
2] inhibitor) and NPIMA (COX 2 inhibitors) (all 10 μM). Surface CFTR was
to measure functional CFTR correction in BHK cells expressing F508del-CFTR
lone (DMSO 0.1%) and the positive control is wild-type cells. All compounds
F508del-CFTR rescue in human bronchial epithelia (CFBE41o−). Short-circuit
s to VRT-325 (10 μM), ibuprofen (10 μM), SC-560 (1 μM), DUP-697 (1 μM),
used to determine signiﬁcance, *p b 0.05, **p b 0.01, ***p b 0.001.(D) Surface
after siRNA knockdown of expression of COX 1 and COX 2 (separately and in
0.1%) (Control), wild-type cells (positive control) and ibuprofen (10 μM). The
t was for 24 h. Data are presented as mean ± S.E.M. (E) Cell surface CFTR levels
ncentrations of ibuprofen (1 pM, 10 pM, 100 pM, 1 nM, 10 nM, 100 nM 1 μM,
1 (green), COX 2 (blue) and COX 1 and 2 together (pink). COX enzymes were
down was monitored by quantitative PCR and shown to be similar to that found in
entration of ibuprofen used, ﬁrstly a mock transfection with no ibuprofen present
ent (ibuprofen red). Data are presented as mean ± SD. Signiﬁcance compared with
0.001.
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trafficking. Similar to the results obtained in Fig. 5A and B
using pharmacological inhibitors of COX1 and COX2 here
utilizing siRNA against COX 2 did not induce correction
whereas siRNA knockdown of COX 1 triggered a small
correction. Intriguingly, in cells deficient in both COXs the
level of correction was not significantly different from the COX-1
only knockdown response. Further none of the knockdowns
reached the ibuprofen level of correction. Messenger RNA
reduction upon siRNA treatment as measured by real-time PCR,for both COX 1 and 2 was reduced by 76 to 78% of control levels
(Supplementary Fig. 6A), with a similar reduction in protein level
(Supplementary Fig. 6B and C). To confirm the link between
COX inhibition and ibuprofen correction of F508del-CFTR
ibuprofen correction was tested over a range of concentrations in
combination with the siRNA knockdown of both COX 1 and
COX 2 separately and together (Fig. 5E). Using the sameHEK293
FACS assay system as Fig. 5D it was found that upon knockdown
of COX-1 alone and in combination with COX-2 less ibuprofen
was required for the same level of CFTR correction to be
24 G.W. Carlile et al. / Journal of Cystic Fibrosis 14 (2015) 16–25obtained. Upon comparison of the results between ibuprofen alone
(red line) and ibuprofen plus COX-1 (green line) knockdown
the EC50 dropped to 19.5 ± 2.9 μM from 208.4 ± 1.8 μM. This
was not the case for ibuprofen plus COX-2 knockdown (blue line)
which was the same as the ibuprofen only. It should be noted
that similar levels of siRNA were knockdown obtained as those
in Fig. 5D (Supplementary Figure A). Hence the evidence
strongly suggests that ibuprofen is able to partially correct the
trafficking of F508del-CFTR, and that this occurs via the
inhibition of COX 1.
4. Discussion
We identified the drug ibuprofen, a non-steroidal anti-
inflammatory (NSAID), as a CFTR corrector. Previously benefi-
cial responses to ibuprofen in CF patients have been interpreted as
resulting from its anti-inflammatory activity. However, we show
that ibuprofen partially corrects the trafficking of F508del-CFTR,
both in vivo and in-vitro using concentrations (10 μM) that were
achieved in the plasma of patients during trials. While this study
does not challenge the understanding that ibuprofen's ability to
moderate inflammation is beneficial to CF patients it is suggestive
that at least part of the beneficial effects of ibuprofen treatment are
due to its ability to rescue F508del-CFTR.
Ibuprofen gave F508del-CFTR trafficking correction in all
assays tested but the amount of the correction varied between 2
and 26% of wild-type response. The reason for this variation is
unclear but may reflect differences in CFTR expression level, cell
polarization or due to species differences in a cellular context
[20]. Research has shown that pig and mouse F508del-CFTR are
less misprocessed than human CFTR due to species differences
between CFTR protein sequences [20]. Response in CFBE cells
was significantly less compared to BHK cells even though both
were expressing human CFTR. This suggests that expression
level and the species dependent cellular context are more critical
than CFTR species. Cell type variation was also observed after
Aha1 knock down which increased F508del-CFTRmaturation in
HEK293 but not CFBE cells [21].
The amount of correction required for clinical benefit is
unknown, but estimates range from 6 to 10% of wild-type
CFTR function to 25% of wild-type expression [22,23]. Hence
the ibuprofen mediated CFTR function (1–3%) is low but must
be taken in context. Given the chronic nature of CF and the patient
genetic background variability this increase over time may prove
significant. Ibuprofen's correction althoughmodest is comparable
with other reported correctors (except for VX809) [24].
Recent research has provided evidence that F508del-CFTR
contains more than one folding and processing flaw and therefore
that multiple compounds may be necessary to address each of
these flaws [25]. This has lead to the widely held understanding
that combinations of correctors will be needed to reach therapeutic
levels of CFTR rescue. It is reasonable to assume that in order to
obtain an additive or synergistic response from a combination of
correctors it is necessary that the correctors work on comple-
mentary but different aspects of correction. There are currently
three drugs in the clinical process VX-809, VX-661 and N6022.
Of these the most advanced is VX-809, this has had some limitedsuccess in patients as a mono therapy [24]. It is currently
being tested in combination with the CF potentiator VX-770
(Kalyedeco) and while reports suggest that this gives an improved
effect it is still unclear if this is going to be sufficient to alleviate
CF. As for VX-661 it is a structural analogue of VX-809 and
therefore would not be expected to act in synergy with VX-809.
The drug N6002 is a relatively new experimental drug in a phase
1 clinical trial and it is too early to determine the outcome. Hence
it is entirely possible that if VX-809 does come to clinic that it
will have to be in combination with some other corrector or
correctors and that there is no other corrector likely to be available
in the near future. In this circumstance the rationale for testing and
identifying correctors from drugs that are already clinically
available and can be rapidly repurposed for CF becomes sound.
Such compounds have known bioavailability and toxicity. Hence
with this in mind it is interesting to note that upon testing ibuprofen
in combination with several other published correctors it was
additive in nature to some of the correctors including VX-809
(Suppl. Fig. 4). Therefore given the need for and lack of near term
combination partners for VX809 it may be possible to make a
plausible rationale for using ibuprofen as a member of a future
drug combinationmay be based on the following points. Ibuprofen
has the ability to obtain an additive response between ibuprofen
andVX-809. Ibuprofen has a long and generally positive history in
CF treatment and it is immediately available [11,12].
We found that ibuprofen did not demonstrate any ability to
correct any of the three other misfolded proteins involved on
conformational disorders that we tested (Supplementary Fig. 5).
Given that all three misfolded proteins tested Vasopressin
receptor 2 [20], human ether-a-go-go [20] and sulphonyl urea
receptor 1 [20] have links to aspects of inflammation. This
suggests that the ibuprofen mechanism of action is not a common
inflammatory response to misfolded protein from the ER and not
a generalized proteostatic modulation but rather something more
specific in nature. Our results utilizing specific pharmacological
inhibitors and siRNAs that target COX 1 in particular suggest that
ibuprofen's ability to rescue F508del-CFTR requires prostaglan-
din synthesis. The results indicate that ibuprofen can act to
improve F508del-CFTR trafficking through a mechanism that
involves inflammatory signaling. Hence the reported slowing of
CF lung function decline by ibuprofen [10–12] may be partially
due to correction of F508del-CFTR rather than inflammation
reduction.
High ibuprofen concentrations have been reported to block
CFTR channel activity [26], however in this study high ibuprofen
concentrations (320 μM) gave stronger correction, agreeing with
recent work, which suggested that if cAMP was maintained near
endogenous levels, CFTR channels function in the presence of
high dose ibuprofen [27]. Despite reports suggesting that ibuprofen
reduces CFTR expression [28] we did not detect this indeed,
ibuprofen increased CFTR protein expression without affecting
the level of CFTR mRNA (data not shown).
Ibuprofen's ability to partially correct F508del-CFTR mis-
localization may involve its COX1 inhibition. Interestingly,
COX1 and COX2 are reported to be modifiers of CF disease
severity in which polymorphisms that reduce the amount of COX
correlated with less severe disease [29]. COX inhibitors have also
25G.W. Carlile et al. / Journal of Cystic Fibrosis 14 (2015) 16–25been shown to inhibit PDE4 and PDE5 [30] suggesting a link
between ibuprofen and PDE5 mediated correction [19]. Ibuprofen
is presently given to 3.5% of CF patients as an anti-inflammatory
(CFF registry 2010). Our data shows that COX1 inhibitors can
partially correct F508del-CFTR trafficking, to a level that is similar
to ibuprofen, suggesting that the prostaglandin biosynthesis is a
novel pathway and that the further exploration of the NSAIDs
drug family for more potent correctors may well worth future
investigation in CF.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2014.06.001.Acknowledgments
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